| REFINE: Regorafenib observational study in hepatocellular carcinoma |
Ongoing |
Stivarga (regorafenib) |
4 |
19244 |
King Fahad Specialist Hospital (Dammam), King Khalid University Hospital (Riyadh),King Fahad Medical City (Riyadh),King Fahad Medical City (Riyadh),King Fahad Medical City (Riyadh), My Clinic (Jeddah) |
| An open label, Phase IV, multicenter study to Assess the efficacy and safety of Elica-MTM Cream Containing Miconazole nitrate 2% w/w and Mometasone furoate 0.1% w/w) in Napkin Dermatitis with Inflamed Skin Conditions of Eczema or Dermatitis Caused by Infection With Certain Fungi and Bacteria |
Ongoing |
Elica-M |
4 |
ELICA-M001 |
King Abdulaziz University Hospital (Jeddah), King Khalid University Hospital (Riyadh) |
| UPDATES: A prospective non-interventional study investigating the treatment effect of Tresiba® in adult patients with type 2 diabetes in Saudi Arabia |
Ongoing |
Tresiba |
4 |
NN1250-444 |
Dr. Soliman Fakeeh Hospital (Jeddah), Security Force Hospital (Riyadh), Umm Al-Qura University (Makkah), Dr. Sulaiman Al Habib Medical Group, King Fahad Medical City (Riyadh), Specialized Medical Center (Riyadh), Almana Hospital (Jubail), Saudi German Hospital (Jeddah), Almana Hospital (Ahsa), Almana Hospital (Khobar), Mouwasat Hospital (Qatif), Almana Hospital (Dammam), King Abdulaziz University Hospital (Jeddah), King Fahad Hospital of the University, My Clinic (Jeddah), United Doctors (Jeddah), Mouwasat Hospital (Khobar), Agrass Medical Complex (Jeddah) |
| MultiZonal obsERvational study conducted By clinIcal practitioners on Repatha® use iN subjects with hyperlipIdemia - ZERBINI |
Ongoing |
Repatha |
4 |
2016.03.27 |
Saud Al-Babtain Cardiac Center (Dammam), King Fahd Military Medical Complex (Dhahran), King Khalid University Hospital (Riyadh), King Abdulaziz University Hospital (Jeddah), Armed Force Hospital (Taif), Armed Force Hospital (Khamis Mushait), Prince Sultan Cardic Center (Riyadh) |
| Post-authorization safety study in patients with type 2 diabetes mellitus to assess the incidence of ketoacidosis, severe complications of urinary tract infection, volume depletion, and dehydration among patients treated with EMPAGLIFLOZIN or DPP-4 inhibitors in Saudi Arabia |
Ongoing |
Jardiance |
4 |
1245/149 |
Armed Force Hospital (Al-Hada), King Fahad Medical City (Riyadh) |
| AURIGA / An observationAl stUdy pRogram toInvestiGate the effectiveness of intravitreal Aflibercept indiabetic macular edema and/or macular edema secondary toretinal vein occlusion in a real world setting. |
Ongoing |
Aflibercept |
4 |
19157 |
King Faisal Specialist Hospital and Research Center (Riyadh), King Faisal Specialist Hospital and Research Center (Jeddah), King Khalid University Hospital (Riyadh), King Khaled Eye Specialist Hospital (Riyadh) |
| A single-arm interventional Phase IV, post-authorisationstudy evaluating the safety of pediatric patients withtransfusional hemosiderosis treated with deferasiroxcrushed film coated tablets |
Ongoing |
Deferasirox |
4 |
CICL670F24 |
King Abdulaziz Medical City NG (Jeddah) |
| "A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlledClinical Study to Evaluate the Safety and Efficacy of Ertugliflozin (MK-8835/PF-04971729)in Pediatric Participants (ages 10 to 17 years, inclusive) with Type 2 Diabetes Mellitus" |
Ongoing |
Ertugliflozin |
3 |
MK-8835-059-00 |
King Salman Hospital (Riyadh), King Abdulaziz Medical City NG (Jeddah), King Fahad Medical City (Riyadh) |
| Adjunct Low Dose Ketamine Infusion Versus Standard of Care in Mechanically Ventilated Critically Ill Patients at a Tertiary Saudi Hospital (ATTAINMENT Trial): Randomized, Prospective, Pilot Trial |
Ongoing |
Ketamine |
3 |
2191187 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| A Randomized, Multicenter, Open-Label, Phase 3 Study to Compare the Efficacy and Safety of Acalabrutinib (ACP-196) in Combination with Venetoclax with and without Obinutuzumab Compared to Investigator’s Choice of Chemoimmunotherapy in Subjects with Previously Untreated Chronic Lymphocytic Leukemia Without del(17p) or TP53 Mutation |
Ongoing |
Acalabrutinib |
3 |
D8221C00001 |
King Fahad Specialist Hospital (Dammam) |
